GS7
€15.21
▼-1.23%
Stock
GLAXOSMITHKLINE LS-,25
Official Company Name: GlaxoSmithKline plc
Stock Symbol: GS7
Stock Market: Deutsche Börse - FSX
Currency: Euro - EUR
GS7 Stock Price - 1 Year Price Evolution & Moving Averages
1 Year Return
▼-8.15%
Daily closing prices, with moving averages and volumes - Euro (EUR)
Moving averages:
- — EMA20
- — SMA50
- — SMA200
GlaxoSmithKline plc Categories
United Kingdom
languages
Healthcare
languages
Drug Manufacturers—General
Healthcare
Drug Manufacturers—General
Company Description
GlaxoSmithKline PLC, better known as GSK, is a pharmaceutical company. GSK manufactures products for major disease areas such as asthma, cancer, infections, diabetes, and mental health, and it also has a portfolio of vaccines. Operating in more than 115 countries, GSK is also engaged in the consumer healthcare business in oral health, pain relief, respiratory, nutrition/gastro-intestinal, and skin health categories.
GS7 Stock Data
| Open | €15.15 |
| High | €15.25 |
| Low | €15.15 |
| Close | €15.21 |
| Volume | 2,776 |
| Previous Close | €15.40 |
| 1-Day Change | -0.19 |
| 1-Year Change | -1.35 |
| Average Daily Volume | 3,292 |
| 52-Week High | €21.66 |
| 52-Week Low | €15.21 |
Disclaimer
All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!
Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.
Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).
Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.
Please conduct your own due diligence to verify insights.